Academic: I hold two doctorates, a DVM from Ohio State University (1984) and a Ph.D. in Pharmacology and
Toxicology from the University of Arizona (1994). I completed an NRSA-funded post-doctoral fellowship at the
Arizona Cancer Center. Following employment in the biotech sector developing human genetic testing
platforms I joined the University of Arizona in 2000 as an Associate Research Scientist, and transitioned to a
tenure-track position in Pharmacology and Toxicology in 2006, where I am currently an Associate Professor.

Research: My academic research has progressed in two complementary paths. My work has studied the
human determinants of individual variability in disease and in response to environmental toxicants. Featured
prominently within that is my keen interest in inherited human genetic variation and its potential impact on
human health. My work has involved numerous IRB-approved studies in populations of human research
participants. Among other findings, our work has identified genetic and non-genetic factors that drive personto-
person differences in ingested arsenic biotransformation, a well-recognized risk factor for human arsenicassociated
disease. My laboratory also has a sustained, funded effort in mechanistic toxicology. We currently
have two funded projects aimed at understanding the carcinogenic mechanism of action of inorganic arsenic
in experimental models of lung cancer. I believe that the translational spectrum of the research that I have led
gives me a unique tool set to bring to the HSRB.

Teaching, Mentoring, Outreach: I have a longstanding commitment to teaching and to outreach to
communities impacted by environmental contaminants. I am an active educator at the undergraduate,
graduate, and professional course level. I have presented at workshops on ethics pertaining to human
genetics. Last summer I participated in a residential 2-day undergraduate retreat on bioethics, and I have
been invited to return this summer. I am the P.I. of a recently-awarded R25 from NIEHS aimed at providing
two years of training and paid research experience in the environmental health sciences to disadvantaged
undergraduates. As one example of putting teaching and outreach into action, two weeks ago, over spring
break, I led a team of my R25 trainees to the Navajo nation to work on a colleague’s R21 (NIEHS) project
quantifying metal levels in soil, water, and sediment downstream of the Gold King Mine spill. During that visit
I presented a community-understandable summary of the toxicology and potential health impact of selected
metals. I have delivered many similar talk in diverse communities and settings, on both sides of the
US/Mexico border. I cite these examples to emphasize that the experience that I have as a leader of studies
utilizing human participants is within a larger context and value system of respect and empathy that I think is
important in the review of studies involving human participants.

Leadership: I am the Interim Head of the Department of Pharmacology and Toxicology at U. Arizona. At the
college level I am an elected member of the Academic Freedom and Tenure committee. I was recently
appointed as the Chair of the University of Arizona Graduate Council, the shared governance body for
graduate education at U.A. I have served as an elected Counselor, and more recently in the Presidency 4-year
track of the Metals Specialty Section of the Society of Toxicology.